Human melatonin receptors consist of melatonin receptor 1A (MT1) and melatonin receptor 1B (MT2), and possess various biological activations, which include the control of circadian rhythm and immune regulation. Recently, it have been found that melatonin receptors inhibit cell proliferation and have oncostatic properties, which is being researched in the treatment strategies of breast cancer, prostate cancer, and Non-Small Cell Lung Cancer. Also, interest in the effect of melatonin receptor’s correlation to head and neck carcinogenesis and application possibilities on head and neck cancer has been found. However, in head and neck cancer, how melatonin receptor relates and functions with epithelial-mesenchymal transition (EMT), which plays a major role in human carcinogenesis, is yet unknown. In this research, in HSC5 cell and YD15 cell, the head and neck cancer cell lines, a selective melatonin receptor antagonist, Luzindole, was utilized to examine the effect of melatonin receptors on EMT. After treating Luzindole on HSC5 cells and YD15 cells, the authors evaluated cell viability rate with CCK 8 assay, and performing colony forming assay, invasion assay and western blot analysis, to confirm melatonin receptor’s effect on EMT. When Luzindole was treated on HSC5 cells and YD15 cells in low concentration of 100nM, no significant difference in cell viability was found, whereas Luzindole-treated cells had a significantly increase in the invasion assay. As a result of colony forming assay, in YD15 cells, the number of colony formation decreased slightly, whereas in HSC3 cells, the number of colony formation increased. According to the western blotting, no difference in E-cadherin, Slug, and vimentin protein expression was shown. This result of research indicates the possibility of melatonin receptor being related to EMT and new chemotherapeutic target in the carcinogenesis of head and neck cancer.